OptiBiotix Health Plc (OPTIBIOTIX HEALTH PLC ORD 2P) Aktie

OptiBiotix Health Plc, a life sciences company, engages in the discovery and development of microbiome modulation products in the United Kingdom, the United States, India, China, and internationally. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that can impact human physiology and derive potential health benefits. Its products include Slimbiome, which offers a scientifically supported, non-pharmaceutical approach to reduce hunger and cravings; CholBiome, a food supplement for reducing cholesterol and blood pressure and supporting vascular health; and Sweetbiotix which are dietary fibres used as an alternative to sugar and existing sweeteners. The company also provides WellBiome a novel in vitro model of the human gut; OptiBiotics, a portfolio of prebiotics developed to target and enhance the growth of specific probiotics; and SlimBiome X3, a supplement that helps users cut calories without hunger and cravings. The company was formerly known as Ducat Ventures PLC and changed its name to OptiBiotix Health Plc in August 2014. OptiBiotix Health Plc was incorporated in 2006 and is headquartered in York, the United Kingdom.